KalVista Pharmaceuticals (KALV) to Release Earnings on Thursday

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) is anticipated to announce its Q4 2025 earnings results before the market opens on Thursday, July 10th. Analysts expect the company to announce earnings of ($0.83) per share for the quarter.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV traded up $0.12 during mid-day trading on Friday, hitting $11.90. The company's stock had a trading volume of 338,543 shares, compared to its average volume of 491,268. The firm has a market capitalization of $591.67 million, a P/E ratio of -3.20 and a beta of -0.04. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $15.50. The stock's fifty day simple moving average is $12.39 and its two-hundred day simple moving average is $11.00.

Insider Transactions at KalVista Pharmaceuticals

In other news, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was bought at an average cost of $9.42 per share, with a total value of $235,500.00. Following the transaction, the insider directly owned 5,303,985 shares in the company, valued at approximately $49,963,538.70. This represents a 0.47% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $11.84, for a total value of $32,867.84. Following the sale, the insider directly owned 106,611 shares in the company, valued at approximately $1,262,274.24. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,899 shares of company stock valued at $206,176. Corporate insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at approximately $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock valued at $281,000 after acquiring an additional 2,939 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in KalVista Pharmaceuticals by 3.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company's stock valued at $3,923,000 after acquiring an additional 12,263 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have recently commented on KALV. Jones Trading reissued a "buy" rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $24.83.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).